Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases

T-Reuters2021-09-24

Novavax Inc:Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases.Novavax - Results From Nanoflu Influenza Vaccine Phase 3 Clinical Trial Achieved All Primary Endpoints.Novavax Inc - Nanoflu Vaccine Candidate Induced Significantly Enhanced Cell-Mediated Immune Responses.Novavax Inc - Nanoflu Was Well-Tolerated With A Comparable Safety Profile.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
3